Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
about
Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-AnalysisHow I treat pediatric acute myeloid leukemiaChildhood acute myeloid leukaemiaHigh level of miR-196b at newly diagnosed pediatric acute myeloid leukemia predicts a poor outcomeComprehensive mutational profiling of core binding factor acute myeloid leukemia.Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.Biology, risk stratification, and therapy of pediatric acute leukemias: an update.Homeobox gene expression in acute myeloid leukemia is linked to typical underlying molecular aberrations.Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology GroupIntegrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemiaPrognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOGGemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.Who is fit for allogeneic transplantation?Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group.Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemiaGenomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to RelapseLow WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.The adolescent and young adult with cancer: state of the art-- acute leukemias.Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing programTherapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.Molecular diagnosis of acute myeloid leukemia.Epigenetic regulation of miRNA genes in acute leukemia.Therapeutic targeting of c-KIT in cancer.Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemiaNovel therapies for children with acute myeloid leukaemia.Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.How I treat paediatric relapsed acute myeloid leukaemia.Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.Single-nucleotide polymorphism-array improves detection rate of genomic alterations in core-binding factor leukemia.Novel approaches to pediatric leukemia treatment.Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.Cytokines secreted by bone marrow stromal cells protect c-KIT mutant AML cells from c-KIT inhibitor-induced apoptosis.Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.
P2860
Q26771740-9E62ED96-71BA-4242-9E72-42BB33C57A5FQ26992280-E11894EC-D6E4-445C-890C-725A6F868104Q27005960-FA1FB4E2-C9D3-4A55-837D-E328A7D42D8CQ33667247-8858B53B-D93E-41E3-890C-B72A45A91A16Q33758306-015DFA7A-5E52-4ED5-898F-8B62B50052A2Q34052581-60B75D48-504B-4074-8C6F-FEE3BEDBF60EQ34106837-12E8B2B4-4879-4146-9999-AA5A1E28E887Q34663691-CE89AECD-CBF7-4A79-9651-7B67AAB17ABBQ34764504-F36C090C-CD5F-4B00-911E-0CDCE976F8A9Q35025091-904B0F1A-C845-48B1-A4A7-BDC295ACAD4FQ35046171-2BC211B4-881A-4BE9-9092-E165DC08A1DFQ35265916-4920FAFB-7B23-48FA-9046-222DB40965DEQ35525313-E22DEFC5-3164-4E76-BE9B-9B4B811C8B89Q35606252-95802BD6-9810-45B5-9EC2-698127E373D6Q35651744-AF8F2850-AB93-4172-AB79-43434D51AF7FQ35660739-E3A80C0A-4970-40E0-9EB3-3DF5F2CF9C84Q36053792-04A34DF0-CC75-4C6A-897E-78768DF20B88Q36303319-80B9B760-7393-4F68-8180-BA7DCB3732A3Q36548080-41F5A04A-0012-4472-806A-4F18154C4FB4Q36917869-DC280F07-E7AB-4185-A2B3-707D7C3200C0Q36919799-4ABA82EB-67DE-46C4-BA0C-07763663F9B0Q37134753-B62DC90E-B31A-46DD-966F-F5A46A3EF8C2Q37295112-33C58D4D-A1E6-467D-AFB9-4E636D2394D3Q37372832-70AB206A-929A-4666-944D-4F6EE28A357FQ37643136-497A3D46-E655-4810-8057-B938D6E809B4Q37659087-150564BF-8A4F-4B07-8D5E-4AF3C89FB84DQ37809866-EBC67700-B30C-43B0-A673-EB3023AD7CE4Q37965026-C908984C-C61F-465B-9BDF-8DA065BD52ABQ38057806-0AC2D96E-7F9F-428C-9400-469AD451AC88Q38068816-11ADE37A-554C-4CC2-BCD4-0A154E67D536Q38096798-C64C64D0-5CB2-449B-ABDB-14F552ADE7C1Q38196743-7C0A2266-306A-4163-BA40-A52E7CC73955Q38212509-F41A9A5A-8905-4B19-9B42-58F294A488E3Q38263126-48E6521D-6FD2-41A5-938F-F1354F27C8B6Q38315894-DDD786A6-E4E0-4AB6-A858-013406C15945Q38500371-CF354A7A-BBE9-40A1-A744-6549CB6FC136Q38904250-5FE5FC8D-9088-4754-AE84-EF9F3AA573A9Q40100589-9882DED2-9FF0-4E21-BC27-9533D462899CQ41823976-D8EBC29E-E79D-421D-9044-B9F58031DE76Q41973082-D8B425F1-1FAA-4886-943D-771AD85E82E1
P2860
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Prevalence and prognostic sign ...... rative trials for de novo AML.
@ast
Prevalence and prognostic sign ...... rative trials for de novo AML.
@en
type
label
Prevalence and prognostic sign ...... rative trials for de novo AML.
@ast
Prevalence and prognostic sign ...... rative trials for de novo AML.
@en
prefLabel
Prevalence and prognostic sign ...... rative trials for de novo AML.
@ast
Prevalence and prognostic sign ...... rative trials for de novo AML.
@en
P2093
P2860
P50
P1433
P1476
Prevalence and prognostic sign ...... erative trials for de novo AML
@en
P2093
Betsy Hirsch
Beverly J Lange
Craig Hurwitz
David Becton
Howard J Weinstein
Irwin D Bernstein
Jerald P Radich
Jessica A Pollard
Myron Chang
P2860
P304
P356
10.1182/BLOOD-2009-09-241075
P407
P577
2010-01-07T00:00:00Z